Good News For Pozen Inc’s Arthritis Drug

[steaner]

(Ottawa) Pozen Inc, a drug maker have been told by the Food and Drug Administration that their arthritis drug PN 400 meets late clinical trial expectations.
This is great news for the company who can now submit an application to the FDA for the possible approval of their drug, which they have co-developed with AstraZeneca.
Stock traders obviously are pleased in their shares of the company, as stocks have soared upon the FDA report by as much as 36 percent.
The only hold up when it came to the drug was a reported side effect of increased risk of ulcers developing in patients taking it.
Arthritis is a very debilatating condition, that is usually found in the joints, resulting in a lot of pain upon movement.